Fig. 4

The lipid metabolism-related prognostic risk core (LMrisk) predicts therapeutic responses of immune checkpoint inhibitors in colon cancer. A Immune checkpoint genes expression levels in the high and low LMrisk groups in TCGA. B–D Kaplan–Meier survival curves of overall survival among four groups stratified by the LMrisk and expression of PD-L1, PD-1 and CTLA-4. E The LMrisk of colon cancer patients with microsatellite instability-high (MSI-H), microsatellite instability-low (MSI-L) and microsatellite stability (MSS). F The LMrisk of colon cancer patients with different CMS. G The LMrisk of colon cancer patients in four immune subtypes. H The TMB in the high and low LMrisk groups. I Top 15 mutated genes were illustrated in the high and low LMrisk groups. J The LMrisk of the patients with CR/PR and SD/PD. Kaplan–Meier survival curves for the patients according to the LMrisk in IMvigor210 cohort. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. ^*, P < 0.05; ^**, P < 0.01; ^***, P < 0.001; ns, not significant